A total of 126 patients affected by renal cell carcinoma and submitted to radical nephrectomy were treated with immunotherapy with Interferon alone or in combination with Vinblastine. The patients were subdivided into two groups: group 1 = 28 stage IV patients submitted to interferon alpha2b 10,000,000 UI/m2/day three times a week and Vinblastine 0.1 mg/kg/day every 21 days and group 2 = 53 stage I and II patients submitted to interferon beta 6,000,000 UI/day three times a week and 45 stage III and IV patients submitted to interferon beta 6,000,000 UI/day three times a week and Vinblastine 0.1 mg/kg/day every 21 days. The average follow-up was 36 months (range 24-60 months). In group 1 (24 patients) no complete response was found, while partial response was obtained in 4 patients, for an objective response rate of 16.6%. In group 2 stages I and II (49 patients) 84% of patients survived to a follow-up of 36 months. In group 2 stage III (30 patients) stabilization of the disease was established in 66% of cases to an average follow-up of 39 months, while in stage IV (15 patients) 33% of patients showed an objective response (5/15). The dose of interferon beta was lower than that of the alpha 2b and so the appearance of toxic effects was also lower. The interferons showed small but reproducible antineoplastic activity. Interferon beta in association with Vinblastine appears to have the same efficacy as the other interferons used until now, with the advantage of being usable at lower doses and greater tolerance.
|Number of pages||4|
|Journal||Acta Urologica Italica|
|Publication status||Published - 1995|
- renal carcinoma
ASJC Scopus subject areas